# A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

> **NCT06659640** · PHASE1,PHASE2 · RECRUITING · sponsor: **Alnylam Pharmaceuticals** · enrollment: 120 (estimated)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia

## Interventions

- **DRUG:** ALN-6400
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06659640
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-07
- **Primary completion:** 2028-01-05
- **Final completion:** 2028-06-22
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06659640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06659640, "A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT06659640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*